{"id":45069,"date":"2022-06-14T17:02:57","date_gmt":"2022-06-14T15:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mtor-mammalian-target-of-rapamycin-inhibitors-market-analysis-report-2022-by-drug-type-indication-route-of-administration-forecast-to-2030-researchandmarkets-com\/"},"modified":"2022-06-14T17:02:57","modified_gmt":"2022-06-14T15:02:57","slug":"mtor-mammalian-target-of-rapamycin-inhibitors-market-analysis-report-2022-by-drug-type-indication-route-of-administration-forecast-to-2030-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mtor-mammalian-target-of-rapamycin-inhibitors-market-analysis-report-2022-by-drug-type-indication-route-of-administration-forecast-to-2030-researchandmarkets-com\/","title":{"rendered":"mTOR (Mammalian Target of Rapamycin) Inhibitors Market Analysis Report 2022 by Drug Type, Indication, Route of Administration – Forecast to 2030 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nIncreasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period.\n<\/p>\n

\nFor instance, in June 2021, Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress). Everolimus tablets will be in strength of 0.25mg, 0.5mg, and 0.75mg.\n<\/p>\n

\nIncreasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market. For instance, according to an article published by the U.S. Department of Health and Human Services, published in 2018, there were an estimated 582,727 people living with kidney and renal pelvis cancer in the U.S.\n<\/p>\n

\nMammalian target of rapamycin (mTOR) is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. Mammalian target of rapamycin (mTOR) inhibitors controls the cell division, and controls the growth of cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow.\n<\/p>\n

\nMammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and it is being studied for use in other types of cancers. mTOR are indicated for the treatment of breast cancer, lymphangioleiomyomatosis, neuroendocrine carcinoma, organ transplant, pancreatic cancer, renal cell carcinoma, tuberous sclerosis complex and others. Mammalian target of rapamycin (mTOR), drugs are- Everolimus, Temsirolimus, and Sirolimus.\n<\/p>\n

\nMammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.\n<\/p>\n

\nKey features of the study:<\/strong>\n<\/p>\n